COMP360 Psilocybin Therapy
Treatment-Resistant Depression (TRD)
Key Facts
About Compass Pathways
Compass Pathways is a clinical-stage biotech company on a mission to accelerate patient access to evidence-based innovation in mental health. Its core strategy is the development of COMP360, a proprietary synthetic psilocybin, integrated with psychological support, currently in a global Phase 3 program for treatment-resistant depression (TRD). The company aims to establish a new paradigm in mental healthcare by addressing conditions where existing treatments are inadequate, leveraging rigorous science and a patient-centric approach.
View full company profileAbout Compass Pathways
Compass Pathways is a clinical-stage biotech company on a mission to accelerate patient access to evidence-based innovation in mental health. Its core strategy is the development of COMP360, a proprietary synthetic psilocybin, integrated with psychological support, currently in a global Phase 3 program for treatment-resistant depression (TRD). The company aims to establish a new paradigm in mental healthcare by addressing conditions where existing treatments are inadequate, leveraging rigorous science and a patient-centric approach.
View full company profileAbout Compass Pathways
Compass Pathways is a clinical-stage biotech company on a mission to accelerate patient access to evidence-based innovation in mental health. Its core strategy is the development of COMP360, a proprietary synthetic psilocybin, integrated with psychological support, currently in a global Phase 3 program for treatment-resistant depression (TRD). The company aims to establish a new paradigm in mental healthcare by addressing conditions where existing treatments are inadequate, leveraging rigorous science and a patient-centric approach.
View full company profileTherapeutic Areas
Other Treatment-Resistant Depression (TRD) Drugs
| Drug | Company | Phase |
|---|---|---|
| CYC-126 | Cyclerion Therapeutics | Phase 1 |
| FMP374 | FundaMental Pharma | Preclinical |
| R-107 | Tasman Therapeutics | Phase 3 |
| GH001 | GH Research | Phase 2b/3 |
| Ketamir-2 (Ketamir) | MIRA Pharmaceuticals | Phase 1 |